Abstract Number: 2241 • 2019 ACR/ARP Annual Meeting
Parent Perspectives on Addressing Emotional Health for Youth with Juvenile Myositis: A Qualitative Focus Group Study
Background/Purpose: While juvenile myositis (JM) can negatively affect quality of life, studies of the emotional health needs of youth with JM are limited. We examined…Abstract Number: 2727 • 2019 ACR/ARP Annual Meeting
Mitochondrial Contribution to Juvenile Dermatomyositis Pathogenesis
Background/Purpose: Though mainly found intracellularly, we recently observed mitochondrial extrusion upon cell death, contributing to inflammation and organ damage in lupus-prone mice. Of note, mitochondria…Abstract Number: 93 • 2019 ACR/ARP Annual Meeting
Interferon Pathway Activation in T Follicular Helper (Tfh) Cell Subsets in Human Myositis
Background/Purpose: T and B cells come together in ectopic lymphoid aggregates in myositis, suggesting that local T:B cell interactions could play a role in disease. …Abstract Number: 390 • 2019 ACR/ARP Annual Meeting
Preliminary Response to Janus Kinase (JAK) Inhibition with Baricitinib in Refractory Juvenile Dermatomyositis
Background/Purpose: Juvenile dermatomyositis (JDM) is a systemic autoimmune disease with a prominent interferon (IFN) signature. Treatment often requires prolonged high-dose steroids and other immunosuppressive medications.…Abstract Number: 399 • 2019 ACR/ARP Annual Meeting
Seasonal and Temporal Analyses of Disease Onset and Diagnosis in Myositis Autoantibody Phenotypes in Juvenile Dermatomyositis (JDM)
Background/Purpose: Published studies suggest seasonal occurrence of disease onset and disease activity in patients with adult idiopathic inflammatory myopathies (IIM).Our objective was to evaluate seasonal…Abstract Number: 433 • 2019 ACR/ARP Annual Meeting
Comparison of PROMIS Computerized Adaptive Testing-Administered Item Banks versus Fixed Short Forms in Juvenile Myositis
Background/Purpose: Compared to healthy children, youth with juvenile myositis (JM) often report poorer health-related quality of life (HRQoL). Legacy HRQoL measures may underestimate the impact…Abstract Number: 771 • 2019 ACR/ARP Annual Meeting
Von Willebrand Factor Is Localized in the Extravascular Tissue of Patients with Juvenile Scleroderma
Background/Purpose: Von Willebrand Factor (VWF) is a glycoprotein synthesized in endothelial cells and megakaryocytes that has an essential role in primary hemostasis. There is increasing…Abstract Number: 788 • 2019 ACR/ARP Annual Meeting
Type I Interferon Score and Interferon Induced Mediators CXCL10 and Neopterin Are Correlated with Disease Activity in Juvenile Dermatomyositis
Background/Purpose: Interferons (IFNs) seem to play an important role in the pathogenesis of juvenile dermatomyositis (JDM). Our group previously reported that expression of both type…Abstract Number: 1751 • 2019 ACR/ARP Annual Meeting
A Systematic Literature Review of Efficacy and Safety of Biologic Agents for the Treatment of Juvenile Dermatomyositis
Background/Purpose: Juvenile dermatomyositis (JDM) is a rare, chronic autoimmune illness characterized by symmetric, proximal muscle damages and involvement of the skin. While first line treatment…Abstract Number: 1868 • 2019 ACR/ARP Annual Meeting
Clinical Correlations of Autoantibodies Against Heat Shock Cognate 71 kDa Protein in Patients with Juvenile Dermatomyositis
Background/Purpose: Juvenile dermatomyositis (JDM) is an inflammatory myopathy characterized by prominent vascular and perivascular inflammation in affected skeletal muscles. The mechanisms of vessel injury in…Abstract Number: 1871 • 2019 ACR/ARP Annual Meeting
Myositis-Specific Antibodies and Muscle Histopathology in Juvenile Dermatomyositis: New Insights into the Mechanism of Injury
Background/Purpose: Myositis-specific antibodies (MSAs) are identified in over half of children with JDM and are associated with distinct clinical phenotypes. MSA subtype, in combination with…Abstract Number: 481 • 2018 ACR/ARHP Annual Meeting
Stepping It up: The Use of Physical Activity Monitors As an Outcome Measure in Juvenile Myositis
Background/Purpose: The use of physical activity monitors (PAM), which objectively quantify free-living movement, may enhance assessment of disease activity in juvenile myositis (JM) clinical trials…Abstract Number: 1332 • 2018 ACR/ARHP Annual Meeting
Proteomic Discovery Analysis Identifies Unique Proteins and Pathways Correlating with Different Clinical Activity and Damage Measures in Juvenile Dermatomyositis (JDM)
Background/Purpose: JDM is a complex heterogeneous autoimmune disease. To define biomarkers and better understand JDM pathogenesis, aptamer-based proteomic technology was used to mine the serum…Abstract Number: 1347 • 2018 ACR/ARHP Annual Meeting
A Semi-Quantitative Whole Body Magnetic Resonance Imaging Assessment Tool to Define Musculoskeletal Abnormalities in Patients with Idiopathic Inflammatory Myopathies
Background/Purpose: There is a lack of standardized methodology for assessing whole body MRI (WBMRI) in idiopathic inflammatory myopathy (IIM) patients. This leads to difficulty in…Abstract Number: 1402 • 2018 ACR/ARHP Annual Meeting
The Relationship of Pain, Fatigue and Emotional Distress with Quality of Life in Juvenile Myositis
Background/Purpose: Juvenile Myositis (JM) is an autoimmune disease that negatively impacts quality of life (QoL) outcomes via muscle weakness and vasculopathic rashes. The relative contribution…